Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Resonate Group, an ambitious Nigerian indigenous company with global aspirations, that aligns her vision with strategic intent to provide innovative solutions and services in Oil & Gas, Maritime, Manufacturing, Finance, Steel, Healthcare, and Supply Chain sectors of the Nigerian economy...
Recent Post
October 5, 2026
US BLM sets December California oil, gas lease sale
Copyright 2024 - All Rights Reserved By Resonate Group | Designed By Nysut Digital Studios